Adipotide is an investigational fat-targeted proapoptotic peptidomimetic designed to ablate white-adipose vasculature

Adipotide (also called FTPP or Prohibitin-TP01) is an investigational peptidomimetic built from a white-fat vascular homing motif linked to a proapoptotic mitochondrial-disrupting domain. Its core idea is unusual: instead of suppressing appetite through CNS pathways or mimicking gut hormones, adipotide is designed to bind endothelial cells in white adipose tissue, trigger apoptosis in the supporting vasculature, and thereby shrink fat mass. The best-known efficacy data are preclinical, especially in rodents and obese Old World monkeys. It is not FDA- or EMA-approved.

Additional Benefits of Adipotide Under Investigation

2. Molecular Mechanism of Action

2.1 Receptor / Target Pharmacodynamics

Adipotide uses a cyclic homing motif, CKGGRAKDC, identified by in-vivo phage display, to target prohibitin on endothelial cells in the vasculature of white adipose tissue. That homing segment is fused to D(KLAKLAK)2, an amphipathic proapoptotic peptidomimetic that disrupts mitochondrial membranes after receptor-mediated internalization. The combined construct is intended to selectively induce apoptosis in fat-associated vascular endothelium.

2.2 Down-stream Biology

3. Pharmacokinetics

Route:
Published efficacy studies used parenteral administration, typically subcutaneous injection in rodent studies, and the first-in-human program was described as a single 28-day cycle in patients with advanced prostate cancer and obesity.

Absorption / half-life:
I did not find a robust peer-reviewed human pharmacokinetic paper for adipotide. Public trial descriptions mention that Phase 1 intended to assess PK, but I did not find published human PK results.

Distribution / clearance:
The primate paper’s renal findings suggest that cleared adipotide or its handling in the proximal tubule may be relevant to toxicity, and the authors explicitly discuss possible competitive effects on tubular creatinine secretion. That makes renal handling a central translational issue.

Formulation practicality:
Unlike once-weekly obesity drugs, adipotide’s public preclinical/clinical-development framing was not built around long half-life endocrine signaling; it was a targeted cytotoxic peptide strategy, which likely contributed to a very different tolerability and development profile.

4. Pre-clinical and Clinical Evidence

4.1 Rodent obesity models

Earlier mouse and rat studies reported that the proapoptotic peptide reduced body weight and fat mass in ob/ob mice, diet-induced obese mice, and obese rats. In one mouse protocol, animals receiving daily subcutaneous peptide treatment over 27 days showed marked body-weight reduction, and the paper concluded that the reduction was primarily body fat and occurred with decreased food intake rather than increased energy expenditure.

4.2 Obese nonhuman primates

The best-known translational study is the 2011 Science Translational Medicine report in obese Old World monkeys. The authors reported rapid weight loss, imaging-confirmed reduction in white adipose tissue, predominant visceral fat loss, and improved insulin resistance. In treated monkeys, insulin AUC fell by more than 60% in two animals in one part of the study, and the fixed-dose study showed a substantial drop in the average insulinogenic index.

4.3 Human evidence

A public ClinicalTrials.gov entry and company press releases show that a first-in-human Phase 1 program was initiated to identify the highest tolerable dose of PROHIBITIN-TP01 / adipotide in patients with advanced prostate cancer and obesity, with PK and weight-related measures among the planned assessments. However, I did not find peer-reviewed human efficacy or safety results from that program.

Evidence quality note:
Adipotide has much stronger preclinical than clinical support. The headline metabolic effects come from animal studies, especially the monkey study, while human translation remains limited and publicly incomplete.

5. Emerging Clinical Interests

6. Safety and Tolerability

Main preclinical liability:
The most important safety signal in primates was renal proximal-tubule dysfunction/injury. The monkey paper describes these renal changes as predictable and reversible at experimentally determined optimal doses, but they were still the primary adverse effect and a major barrier to straightforward obesity-drug development.

GI tolerability / mechanism-related adverse effects:
Adipotide was not developed as a gut-acting appetite suppressant or fat-absorption blocker, and the available preclinical discussion does not center on the classic GLP-1-like nausea profile or orlistat-like steatorrhea profile. Instead, its main concern is targeted cytotoxicity with renal handling concerns.

Human safety profile:
There is no established human safety profile in the literature I could verify. The public Phase 1 trial listing and press materials show the program entered human testing, but I did not find a peer-reviewed publication establishing a tolerated dose, reproducible efficacy, or longer-term safety profile.

Comparative safety / translational matrix

This is why adipotide is scientifically interesting but much less clinically mature than modern incretin-based obesity therapies.

7. Regulatory Landscape

Approval status:
Adipotide is investigational and has no marketing authorization that I could verify from FDA/EMA-facing public sources. Arrowhead announced FDA clearance in 2012 to initiate a Phase 1 study, but that is not the same as approval.

Programs:
Public records show a first-in-human program in the obesity/prostate-cancer setting, but I did not find evidence of later-stage development, approved labeling, or published pivotal human trials.

Use outside research:
Because human evidence is sparse and the main preclinical safety issue was renal toxicity, adipotide is best understood as a research-stage compound, not a clinically established weight-loss therapy.

8. Future Directions

• A safer adipose-targeting vascular approach would likely need a better therapeutic index than the original adipotide construct.

• Any revival of the concept would need clear human PK, kidney-safety mitigation, and modern dose-ranging studies.

• The most durable scientific contribution of adipotide may be as a proof of concept that adipose mass can be manipulated through its vasculature, rather than as a near-term commercial obesity medicine.

Selected References

• Barnhart KF, et al. A Peptidomimetic Targeting White Fat Causes Weight Loss and Improved Insulin Resistance in Obese Monkeys. Science Translational Medicine (2011). Core primate paper: rapid weight loss, visceral-fat reduction, insulin-resistance improvement, renal signal.

• Kim DH, et al. Peptide Designed to Elicit Apoptosis in Adipose Tissue Endothelium Reduces Food Intake and Body Weight. Diabetes (2010). Rodent work on weight loss, fat loss, and secondary hypophagia.

• ClinicalTrials.gov / NCT01262664. First-in-human Phase 1 listing for PROHIBITIN-TP01 in advanced prostate cancer and obesity.

• Arrowhead press releases (2012). FDA IND clearance and first-patient-dosed announcements for adipotide. Useful for public development history, but not substitutes for peer-reviewed human results.